Screener
Bioventus BVS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | June 27, 2026 | December 31, 2025 |
|---|---|---|
| Long-term debt, less current portion | 229,702 | 278,951 |
| Deferred income tax liabilities | 568 | 433 |
| Other long-term liabilities | 13,213 | 15,348 |
| Total liabilities | 395,934 | 455,112 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ Equity | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued | ||
| Class A common stock, $0.001 par value, 250,000,000 shares authorized as of June 27, 2026 and December 31, 2025, 68,211,818 and 67,097,716 shares issued and outstanding as of June 27, 2026 and December 31, 2025, respectively | 68 | 67 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's total liabilities?
- Bioventus (BVS) reported total liabilities of $395.93M in Q2 2026.
- How has Bioventus's total liabilities changed year-over-year?
- Bioventus's total liabilities decreased by 21.7% year-over-year, from $505.49M to $395.93M.
- What is the long-term trend for Bioventus's total liabilities?
- Over 5 years (2020 to 2025), Bioventus's total liabilities has grown at a 5.4% compound annual growth rate (CAGR), from $350.31M to $455.11M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Bioventus's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude